Get the Stockscreener App
5.63
4.48%
0.28
Nevro Corp stock is traded at $5.63, with a volume of 218.17K.
It is up +4.48% in the last 24 hours and up +12.47% over the past month.
See More
Previous Close:
$5.35
Open:
$5.32
24h Volume:
218.17K
Relative Volume:
0.37
Market Cap:
$218.11M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
563.00
EPS:
0.01
Net Cash Flow:
$-67.42M
1W Performance:
+6.47%
1M Performance:
+12.47%
6M Performance:
-50.49%
1Y Performance:
-65.22%
1-Day Range:
$5.22
$5.66
1-Week Range:
$5.10
$5.71
52-Week Range:
$4.382
$22.64
Nevro Corp Stock (NVRO) Company Profile
Name
Nevro Corp
Sector
Industry
Phone
650-251-0005
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-21-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| May-31-23 | Initiated | RBC Capital Mkts | Outperform |
| May-15-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Jan-17-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Downgrade | Piper Sandler | Neutral → Underweight |
| Dec-20-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Apr-13-22 | Resumed | Truist | Hold |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-09-21 | Downgrade | Truist | Buy → Hold |
| Aug-05-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-05-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-05-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-09-21 | Downgrade | Redburn | Buy → Neutral |
| Jul-06-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-02-21 | Initiated | Piper Sandler | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-08-20 | Upgrade | UBS | Sell → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Mar-20-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-20-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-28-18 | Initiated | UBS | Sell |
| Nov-07-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-06-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-06-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-19-18 | Downgrade | Goldman | Neutral → Sell |
| Jul-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-18 | Reiterated | Canaccord Genuity | Buy |
| May-08-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-08-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
View All
Nevro Corp Stock (NVRO) Latest News
Nevro (NVRO) to Release Earnings on Monday - MarketBeat
Nevro (FRA:1N7) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Nevro (NYSE:NVRO) Upgraded to Hold at StockNews.com - MarketBeat
Assenagon Asset Management S.A. Increases Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - PR Newswire
Nevro Corp. (NYSE:NVRO) Receives Average Rating of "Reduce" from Analysts - MarketBeat
President & CEO Thornal Kevin R covered exercise/tax liability with 6,063 shares, decreasing direct ownership by 2% to 249,847 units (SEC Form 4) - Quantisnow
Chronic Pain Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AstraZeneca, Regenacy Pharma, Nevro Corp., Erchonia Corporation - The Globe and Mail
StockNews.com Upgrades Nevro (NYSE:NVRO) to Hold - MarketBeat
Trading (NVRO) With Integrated Risk Controls - Stock Traders Daily
Nevro announces new inducement grants - Medical Buyer
StockNews.com Lowers Nevro (NYSE:NVRO) to Sell - MarketBeat
Nevro shares target cut by Baird, retains neutral stance - Investing.com Australia
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Marketscreener.com
Nevro Corp (NVRO) PT Lowered to $5 at Baird - StreetInsider.com
Nevro Corp. (NYSE:NVRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 - BioSpace
Millennium Management LLC Increases Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat
Here's Why You Should Retain Nevro (NVRO) Stock for Now - MSN
SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.30% to 161,352 units (SEC Form 4) - Quantisnow
Nevro obtains FDA approval for AI-based spinal cord stimulation system - MSN
Nevro Corp. (NYSE:NVRO) Shares Purchased by Point72 Asset Management L.P. - MarketBeat
Nevro Corp. (NYSE:NVRO) Receives $10.55 Consensus Price Target from Brokerages - MarketBeat
Nevro Corp. (NYSE:NVRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Breaking Down Nevro: 10 Analysts Share Their Views - Benzinga
Nevro (NYSE:NVRO) PT Lowered to $6.00 at Citigroup - MarketBeat
Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges - Investing.com India
Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges By Investing.com - Investing.com South Africa
Where are the Opportunities in (NVRO) - Stock Traders Daily
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Shares Sold by Fred Alger Management LLC - MarketBeat
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform - Yahoo Finance
Nevro wins FDA nod for AI-driven spinal cord stimulation tech - Mass Device
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation - PR Newswire
Global Electrotherapy System Research Report 2024: A $1.65 Billion Market by 2030 - GlobeNewswire Inc.
Nevro Corp. (NYSE:NVRO) Stake Raised by Acadian Asset Management LLC - MarketBeat
Vanguard Group Inc's Strategic Reduction in Nevro Corp Holdings - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Nevro (NYSE:NVRO) Share Price Passes Below 50-Day Moving Average of $7.62 - MarketBeat
Microelectronic Medical Implants Market Report 2024-2029, with Profiles of Leading Players, including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro - Yahoo Finance UK
(NVRO) Trading Report - Stock Traders Daily
SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 817 shares, decreasing direct ownership by 0.50% to 163,590 units (SEC Form 4) - Quantisnow
Nevro to Present at Wells Fargo 2024 Healthcare Conference - The Malaysian Reserve
Nevro (NYSE:NVRO) Lowered to "Sell" at StockNews.com - MarketBeat
Assenagon Asset Management S.A. Has $6.13 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
Nathan B Pliam Net Worth (2024) - GuruFocus.com
Nevro Corp. (NYSE:NVRO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Nevro Corp. (NYSE:NVRO) Given Average Rating of “Reduce” by Brokerages - Defense World
Nevro Corp Stock (NVRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):